Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kioa L. Wijnsma"'
Autor:
Kioa L. Wijnsma, Anne M. Schijvens, Romy N. Bouwmeester, Lonneke A. M. Aarts, Lambertus (Bert) P. van den Heuvel, Charlotte A. Haaxma, Nicole C. A. J. van de Kar
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7604 (2024)
Thrombotic microangiopathy (TMA) in association with RNA exosome encoding mutations has only recently been recognized. Here, we present an infant (female) with an EXOSC5 mutation (c.230_232del p.Glu77del) associated with the clinical phenotype known
Externí odkaz:
https://doaj.org/article/11bad0d79b564a77b0aaa3a179eb8d44
Autor:
Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in
Externí odkaz:
https://doaj.org/article/23408f3b87bb415c8e88c8a8caae52f7
Autor:
Kioa L. Wijnsma, Susan T. Veissi, Sem de Wijs, Thea van der Velden, Elena B. Volokhina, Frank A. D. T. G. Wagener, Nicole. C. A. J. van de Kar, L. P. van den Heuvel
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Shiga-toxin (Stx)-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) is one of the most common causes of acute kidney injury in children. Stx-mediated endothelial injury initiates the cascade leading to thrombotic microangiopathy (TMA),
Externí odkaz:
https://doaj.org/article/22ef7c8852a84e8f8cab9fc3c37f1547
Autor:
Caroline Duineveld, Romy N. Bouwmeester, Kioa L. Wijnsma, F.J. Bemelman, J.W. van der Heijden, S.P. Berger, L.P.W.J. van den Heuvel, Nicole C.A.J. van de Kar, Jack F.M. Wetzels, A.D. van Zuijlen, Dr.SP. Berger, J. van de Wetering, A.P.J. de Vries, J.F.M. Wetzels, J.A.E. van Wijk, A.H.M. Bouts, E.M. Dorresteijn, V. Gracchi, F.A.P.T. Horuz-Engels, M.G. Keijzer-Veen, R.W.G. van Rooij, N.C.A.J. van de Kar, L.P. van den Heuvel
Publikováno v:
Kidney International Reports, 8, 715-726
Kidney International Reports, 8(4), 715-726. ELSEVIER SCIENCE INC
the Dutch aHUS Working Group 2023, ' Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation ', Kidney International Reports, vol. 8, no. 4, pp. 715-726 . https://doi.org/10.1016/j.ekir.2023.01.016
Kidney Int Rep
Kidney International Reports, 8, 4, pp. 715-726
Kidney International Reports, 8(4), 715-726. Elsevier Inc.
Kidney International Reports, 8(4), 715-726. ELSEVIER SCIENCE INC
the Dutch aHUS Working Group 2023, ' Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation ', Kidney International Reports, vol. 8, no. 4, pp. 715-726 . https://doi.org/10.1016/j.ekir.2023.01.016
Kidney Int Rep
Kidney International Reports, 8, 4, pp. 715-726
Kidney International Reports, 8(4), 715-726. Elsevier Inc.
Introduction: Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence. Eculizumab ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7865deffdd1dcfa0e4e75f5c72df14cf
http://hdl.handle.net/2066/292465
http://hdl.handle.net/2066/292465
Autor:
Bryan van den Broek, Michiel van der Flier, Nicole C.A.J. van de Kar, Jack F.M. Wetzels, Marien I. de Jonge, Ronald de Groot, Kioa L. Wijnsma, Jeroen D. Langereis
Publikováno v:
Kidney International, 101, 1293-1295
Kidney International, 101, 6, pp. 1293-1295
Kidney International, 101, 6, pp. 1293-1295
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b66d2c4706f610dc068bf2248b4f1a2e
http://hdl.handle.net/2066/251614
http://hdl.handle.net/2066/251614
Autor:
Jack F.M. Wetzels, Dirk Jan A.R. Moes, Saskia E M Schols, Rob ter Heine, Saskia Langemeijer, Nicole C. A. J. van de Kar, Kioa L. Wijnsma, Elena B. Volokhina, Lambertus P. van den Heuvel, Roger J. M. Brüggemann
Publikováno v:
Clinical Pharmacokinetics, 58, 859-874
Clinical Pharmacokinetics, 58, 7, pp. 859-874
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 58(7), 859-874
Clinical Pharmacokinetics, 58, 7, pp. 859-874
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 58(7), 859-874
Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic prope
Publikováno v:
Pediatric Nephrology (Berlin, Germany)
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morb
Autor:
Lambertus P. van den Heuvel, Jack F.M. Wetzels, Caroline Duineveld, Nicole C. A. J. van de Kar, Elena B. Volokhina, Mendy Ter Avest, Rob ter Heine, Romy N. Bouwmeester, Kioa L. Wijnsma
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology, 11
Frontiers in Immunology
Frontiers in Immunology, 11
Frontiers in Immunology
BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS). In view of the high costs, actual needs of the drug, and increasing evidence in
Autor:
Thea J A M van der Velden, Kioa L. Wijnsma, Susan T. Veissi, Nicole C. A. J. van de Kar, Elena B. Volokhina, Sem de Wijs, L.P.W.J. van den Heuvel, Frank A. D. T. G. Wagener
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, 11
Frontiers in Immunology, 11
Shiga-toxin (Stx)-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) is one of the most common causes of acute kidney injury in children. Stx-mediated endothelial injury initiates the cascade leading to thrombotic microangiopathy (TMA),
Autor:
Jack F.M. Wetzels, Rob ter Heine, Roger J. M. Brüggemann, Kioa L. Wijnsma, Nicole C. A. J. van de Kar
Publikováno v:
Clinical Pharmacokinetics, 59, 1645-1646
Clinical Pharmacokinetics, 59, 12, pp. 1645-1646
Clinical Pharmacokinetics, 59, 12, pp. 1645-1646
Contains fulltext : 229067.pdf (Publisher’s version ) (Closed access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29c6870f479bce5105e74ae927c60214
http://hdl.handle.net/2066/229067
http://hdl.handle.net/2066/229067